Galapagos is a clinical stage biotech company focused on developing novel mode of action medicines. Headquartered in Belgium, the Company employs 400 people and reported 2013 revenues of €160 million. Charles River acquired the BioFocus and Argenta service operations on 1 April Q2 2014 – click here to read more.
Galapagos’ most advanced candidate drug GLPG0634 shows excellent safety and efficacy in rheumatoid arthritis patients and is fully proprietary to Galapagos. With GLPG0634, Galapagos demonstrates its capabilities in developing novel medicines for difficult to cure diseases.